Skip to main content
Cisen Pharmaceutical Co.,Ltd. logo

Cisen Pharmaceutical Co.,Ltd. — Investor Relations & Filings

Ticker · 603367 ISIN · CNE100002VG4 LEI · 836800T7RRJXURVHYS35 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,110 across all filing types
Latest filing 2024-04-22 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 603367

About Cisen Pharmaceutical Co.,Ltd.

https://www.cisen-pharma.com/

Cisen Pharmaceutical Co.,Ltd. is a comprehensive enterprise dedicated to the research, development, production, and marketing of a diverse range of medicinal products. The company specializes in the manufacture of large-volume injections, small-volume injections, and solid oral dosage forms, including tablets and capsules. Its product portfolio addresses critical therapeutic areas such as parenteral nutrition, anti-infectives, cardiovascular health, and anesthesia. Cisen Pharmaceutical maintains an integrated value chain, producing both active pharmaceutical ingredients (APIs) and finished formulations. The organization emphasizes technological innovation and stringent quality management systems to ensure the efficacy and safety of its medical solutions. By leveraging advanced manufacturing capabilities and a robust distribution network, the company provides essential healthcare products to clinical institutions and medical providers.

Recent filings

Filing Released Lang Actions
大信会计师事务所（特殊普通合伙）关于辰欣药业股份有限公司非经营性资金占用及其他关联资金往来情况的专项审计报告
Regulatory Filings
2024-04-22 Chinese
辰欣药业股份有限公司2023年度内部控制评价报告
Audit Report / Information Classification · 95% confidence The document is titled '2023 年度内部控制评价报告' which translates to '2023 Annual Internal Control Evaluation Report'. It discusses the evaluation of the company's internal control effectiveness as of December 31, 2023, including financial and non-financial internal control defects, their identification, and rectification status. The document is a detailed report on internal control evaluation, which aligns with the definition of an Audit Report / Information (AR) as it covers internal control evaluation results and related audit opinions. The document length is 3916 characters, which is relatively short but contains substantive content rather than just an announcement or certification. It is not an Annual Report (10-K) or Interim Report (IR) as it focuses specifically on internal control evaluation rather than full financial performance. Therefore, the best classification is AR (Audit Report / Information). FY 2023
2024-04-22 Chinese
辰欣药业股份有限公司关于续聘会计师事务所的公告
Audit Report / Information Classification · 95% confidence The document is an announcement regarding the company's decision to reappoint an accounting firm (大信会计师事务所) for auditing services for the upcoming fiscal year. It details the accounting firm's background, personnel, independence, audit fees, and the approval process by the board and audit committee. There is no actual financial data or audit report included, only information about the appointment and related procedures. The document length is relatively short (2913 characters) and it serves as a formal announcement rather than the audit report itself. Therefore, it fits best under the category of Audit Report / Information (AR), which includes standalone audit-related announcements and information about audit firms and their appointment, excluding full annual reports. FY 2024
2024-04-22 Chinese
辰欣药业股份有限公司关于使用部分闲置自有资金进行委托理财的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by a company about its decision to use part of its idle funds for entrusted financial management (委托理财). It details the amount, purpose, investment scope, risk control measures, and board approval process. The document is relatively short (3075 characters) and does not contain financial statements or detailed financial data. It is a formal disclosure of a financing-related decision but not a full financial report or earnings release. It is not a report publication announcement since it contains substantive information about the transaction itself. The content fits best under Capital/Financing Update (CAP) as it relates to the company's capital management and investment activities with idle funds.
2024-03-28 Chinese
辰欣药业股份有限公司选聘会计师事务所管理制度（2024年3月）
Governance Information Classification · 95% confidence The document is titled '选聘会计师事务所管理制度' which translates to 'Management System for the Selection of Accounting Firms' for auditing purposes. It details the company's internal policies and procedures for selecting and managing accounting firms, including qualifications, evaluation criteria, procedures, and oversight responsibilities. It does not contain financial statements, audit opinions, or results of audits themselves, nor is it an announcement of a report. Instead, it is a governance-related document outlining internal rules and processes related to audit firm selection and oversight. Therefore, it fits best under Governance Information (CGR). The document length is 4770 characters, which is sufficient for a detailed policy document, not a brief announcement or certification.
2024-03-28 Chinese
辰欣药业股份有限公司关于回购注销部分激励对象已获授但尚未解除限售的限制性股票的公告
Transaction in Own Shares Classification · 100% confidence The document is an official announcement from a company regarding the repurchase and cancellation of restricted shares granted under a 2020 stock incentive plan. It details the number of shares repurchased, the adjusted repurchase price, the reasons for repurchase (employee departure), approvals from board and supervisory meetings, and the impact on share capital. The document is a formal disclosure of a share repurchase and cancellation event related to restricted stock incentives, including legal opinions and board resolutions. It is not a full financial report, earnings release, or management discussion, but a specific announcement about a transaction involving the company's own shares. Therefore, it fits the category of "Transaction in Own Shares (POS)" which covers share repurchase/issuance announcements.
2024-03-28 Chinese

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.